Rational Design of Novel Anticancer Small-Molecule RNA m6A Demethylase ALKBH5 Inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The RNA demethylase ALKBH5 is implicated as an oncogene in various cancers, including leukemia and glioblastoma.
• Targeted inhibition of ALKBH5 presents a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

• To develop and evaluate novel ALKBH5 inhibitors for their antiproliferative effects.
• To assess the cancer-cell-type selectivity of these inhibitors.

Main Methods:

• High-throughput virtual screening of 144,000 compounds to identify potential ALKBH5 inhibitors.
• Enzyme inhibition assays using m6A antibody-based ELISA to verify inhibitor activity.
• Assessment of antiproliferative effects on selected leukemia and glioblastoma cell lines.

Main Results:

• Two compounds, 2-[(1-hydroxy-2-oxo-2-phenylethyl)sulfanyl]acetic acid (3) and 4-{[(furan-2-yl)methyl]amino}-1,2-diazinane-3,6-dione (6), were identified with IC50 values of 0.84 μM and 1.79 μM, respectively.
• Significant suppression of proliferation was observed in HL-60, CCRF-CEM, and K562 leukemia cell lines at low micromolar concentrations (IC50: 1.38–16.5 μM).
• Limited or negligible antiproliferative effects were noted in Jurkat leukemia and A-172 glioblastoma cell lines.

Conclusions:

• ALKBH5 inhibition demonstrates potential as a cancer-cell-type-selective antiproliferative strategy.
• The identified compounds represent promising leads for further development in targeted cancer therapy.